# Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma

> **NCT04922723** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **West Virginia University** · enrollment: 16 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT04922723
- **Lead sponsor:** West Virginia University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-03
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04922723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04922723, "Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04922723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*